Status:
COMPLETED
A Study to Assess the Efficacy of Gefapixant (MK-7264/AF-219), in Participants With Chronic Cough (MK-7264-006)
Lead Sponsor:
Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Conditions:
Chronic Cough
Eligibility:
All Genders
18-80 years
Phase:
PHASE2
Brief Summary
This is a randomised, double-blind, placebo-controlled, crossover, single centre study of gefapixant (AF-219/MK-7264) in participants with idiopathic or treatment resistant chronic cough designed to e...
Eligibility Criteria
Inclusion
- History of cough for more than 8 weeks
- Normal chest radiograph
- Idiopathic or treatment resistant cough (idiopathic defined as a cough for which no objective evidence of an underlying trigger can be determined after investigation or a cough that is unresponsive to 8 weeks of targeted treatment for identified underlying triggers including reflux disease, asthma and post-nasal drip \[treatment-resistant\]).
Exclusion
- Current smoker
- Individuals who have given up smoking within the past 6 months, or those with \>20 pack-year smoking history
- Treatment with an angiotensin-converting-enzyme inhibitor (ACE-inhibitor) as the potential cause of a participant's cough, or requiring treatment with an ACE-inhibitor during the study or within 4 weeks prior to Day 0
- Forced Expiratory Volume (FEV1)/Forced Vital Capacity (FVC) \<60%
Key Trial Info
Start Date :
September 22 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2013
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01432730
Start Date
September 22 2011
End Date
February 21 2013
Last Update
November 24 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.